Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting ...

Continuing PSA screening in older men is common practice but not recommended, highlighting the need for clearer guidance.

MoonLake Immunotherapeutics showed strong performance with sonelokimab, outperforming competitors in clinical trials. Check ...